Fiera Capital Corp Lowers Stock Holdings in Danaher Corporation $DHR

Fiera Capital Corp lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 24.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 100,176 shares of the conglomerate’s stock after selling 32,701 shares during the quarter. Fiera Capital Corp’s holdings in Danaher were worth $19,789,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Danaher in the 1st quarter worth about $833,941,000. Generation Investment Management LLP increased its stake in shares of Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the period. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after acquiring an additional 1,072,617 shares during the last quarter. Finally, Parnassus Investments LLC boosted its position in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 29,728 shares of company stock valued at $6,448,990. Corporate insiders own 11.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on DHR shares. Wells Fargo & Company reaffirmed a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Barclays increased their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Evercore ISI boosted their price target on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Guggenheim restated a “buy” rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Trading Up 1.0%

Shares of DHR opened at $221.50 on Friday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The stock’s 50-day moving average is $205.21 and its two-hundred day moving average is $200.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock has a market cap of $156.46 billion, a PE ratio of 45.67, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.71 earnings per share. Equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.